Company intelligence / Profile preview

Aspivix

Ownership: Private
Development stage: Commercial

Overview

Aspivix has developed carevix®, a vacuum-enabled, non-traumatic cervical stabilizer clinically proven to significantly reduce pain (by up to 73%) and bleeding (by up to 78%) compared to the traditional tenaculum used in IUD placements. Clinical trials in Switzerland have demonstrated its safety and efficacy, with published results in reputable medical journals. The device has received both CE marking and FDA clearance as of early 2024. A partnership with Bayer Switzerland aims to accelerate adoption among gynecologists through education, training, and further clinical evidence generation.

Therapeutic areas: Women's Health
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Carevix

Commercial

Indications: Gynecological procedures, IUD insertion

Partnerships

Bayer Switzerland AG (commercialization/education partnership for carevix®)

Beyond the preview

Go deeper on Aspivix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspivix.

Explore the full profile